Acute migraine therapy: recent evidence from randomized comparative trials.

Anna Mett, Peer Tfelt-Hansen

Journal: Current opinion in neurology 2008;21(3):331-7

PMID: 18451718

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

(1) A wide array of data regarding acute migraine treatment are available, but few trials strictly adhere to International Headache Society guidelines for patient inclusion criteria.(2) Triptans appear to have similar efficacy profiles, but among newer triptans, almotriptan offers improved tolerability over sumatriptan.(3) Combination indomethacin/caffeine/prochlorperazine most likely has similar therapeutic efficacy to triptan therapy, with further research needed to complete understanding of any potential differences between these treatments.(4) Multi-targeted combination therapy with a triptan plus a non-steroidal anti-inflammatory (NSAID), such as sumatriptan/naproxen sodium, is more effective in acute migraine treatment than monotherapy with either agent alone.(5) It is unclear whether triptans offer clinically relevant benefits over aspirin or NSAIDs in migraine patients. Thus NSAIDs, particularly effervescent aspirin, should be considered the first-line treatment of migraine attacks.

Address: Wolters Kluwer Health | Adis, Auckland, New Zealand.

DOI: 10.1097/WCO.0b013e3282fee843

Link outs

Free resources

Medical:

https://medlineplus.gov/migraine.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Acute Disease, Analgesics, Anti-Inflammatory Agents, Non-Steroidal, Antiemetics, Caffeine, Central Nervous System Stimulants, Drug Therapy, Combination, Ergotamine, Humans, Indomethacin, Migraine Disorders, Prochlorperazine, Randomized Controlled Trials as Topic, Serotonin Receptor Agonists, Treatment Outcome, Tryptamines, Vasoconstrictor Agents